DPX-Survivac

Phase 2Biologic

IImmunoVaccine Technologies, Inc. (IMV Inc.)

DPX-Survivac is one of 113 biologic programs targeting Fallopian Tube Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fallopian Tube CancerActive, not recruiting

Breast CancerActive, not recruiting

Diffuse Large B-Cell LymphomaRecruiting

Fallopian Tube CancerPhase 2

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

DPX-Survivac

IImmunoVaccine Technologies, Inc. (IMV Inc.)

Phase 2

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 9

Duragesic-100

CCephalon

Preclinical

2 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peritoneal Cancer2 trials

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Completed·IImmunoVaccine Technologies, Inc. (IMV Inc.)·Phase 1·NCT03332576·37 enrolled

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Completed·IImmunoVaccine Technologies, Inc. (IMV Inc.)·Phase 1·NCT01416038·19 enrolled

Breast Cancer1 trial

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT04895761·6 enrolled

Fallopian Tube Cancer1 trial

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT03029403·47 enrolled

Diffuse Large B-Cell Lymphoma1 trial

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting·IImmunoVaccine Technologies, Inc. (IMV Inc.)·Phase 2·NCT04920617·102 enrolled

DLBCL1 trial

DPX-Survivac and Checkpoint Inhibitor in DLBCL

Completed·SSunnybrook Health Sciences Centre·Phase 2·NCT03349450·25 enrolled

1 more indication

Recurrent1 trial

A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL

Terminated·IImmunoVaccine Technologies, Inc. (IMV Inc.)·Phase 2·NCT02323230·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for DPX-Survivac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DPX-Survivac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DPX-Survivac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmunoVaccine Technologies, Inc. (IMV Inc.) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IImmunoVaccine Technologies, Inc. (IMV Inc.)

DPX-Survivac

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peritoneal Cancer2 trials

Breast Cancer1 trial

Fallopian Tube Cancer1 trial

Diffuse Large B-Cell Lymphoma1 trial

DLBCL1 trial

Recurrent1 trial

References

Drug Info

Quick Facts

Related News